The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,171
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,005
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 97
Biological significance of the CpG island methylator phenotype
Suzuki, H., Yamamoto, E., Maruyama, R., Niinuma, T., & Kai, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.007 · Cited by 99
Shenoy, N. K., Bhagat, T. D., Cheville, J. C., Lohse, C. M., Bhattacharyya, S., Tischer, A., Machha, V. R., Gordon-Mitchell, S., Choudhary, G. S., Wong, L.-F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci98747 · Cited by 97
RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis
Zou, Z., Dou, X., Li, Y., Zhang, Z. S., Wang, J., Gao, B., Xiao, Y., Wang, Y., Zhao, L., Sun, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07969-x · Cited by 97
Self-citationVitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia
Mingay, M., Chaturvedi, A., Bilenky, M., Cao, Q., Jackson, L., Hui, T., Moksa, M., Heravi-Moussavi, A., Humphries, R. K., Heuser, M., et al. (2018) · Leukemia · doi:10.1038/leu.2017.171 · Cited by 94
Acute myeloid leukaemia genomics
Medinger, M., & Passweg, J. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14823 · Cited by 98
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
Han, M., Jia, L., Lv, W., Wang, L., & Cui, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00194 · Cited by 99
Zhu, G. G., Nafa, K., Agaram, N. P., Zehir, A., Benayed, R., Sadowska, J., Borsu, L. A., Kelly, C. M., Tap, W. D., Fabbri, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4212 · Cited by 94
Ma, B., Meng, H., Tian, Y., Wang, Y., Song, T., Zhang, T., Wu, Q., Cui, Y., Li, H., Zhang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06804-6 · Cited by 97
Gupta, V. K., Sharma, N., Durden, B. C., Garrido, V. T., Kesh, K., Edwards, D., Wang, D., Myer, C., Mateo-Victoriano, B., Kollala, S. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2562 · Cited by 97
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
Krell, D., Assoku, M., Galloway, M., Mulholland, P. J., Tomlinson, I. P. M., & Bardella, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019868 · Cited by 94
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G. J., & Quintás‐Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 97
Metabolomics in Drug Target DiscoveryPreprint
Rabinowitz, J. D., Purdy, J. G., Vastag, L., Shenk, T. E., & Koyuncu, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010694 · Cited by 98
Natsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Fathi, A. T., & Abdel-Wahab, O. I. (2011) · Advances in Hematology · doi:10.1155/2012/469592 · Cited by 95
Self-citationHematopoietic stem cell fate through metabolic control
Ito, K., & Ito, K. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.05.005 · Cited by 98
IDH1 and IDH2 mutations in pediatric acute leukemia
Andersson, A., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., Radtke, I., Yan, B., Schuetz, J. D., Rubnitz, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.133 · Cited by 96
The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer
Ciccarone, F., Vegliante, R., Leo, L. D., & Ciriolo, M. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.008 · Cited by 97
Kallin, E. M., Rodríguez-Ubreva, J., Christensen, J., Cimmino, L., Aifantis, I., Helin, K., Ballestar, E., & Graf, T. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.007 · Cited by 92
“Several of these mutations have been directly linked to Tet2 loss of function with coordinated reductions in genome-wide hydroxymethylation (Figueroa et al., 2010; Ko et al., 2010).”
BackgroundResultVolchenboum, S. L., Andrade, J., Huang, L., Barkauskas, D. A., Krailo, M., Womer, R. B., Ranft, A., Potratz, J. C., Dirksen, U., Triche, T. J., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.9 · Cited by 94
Clinical significance of T cell metabolic reprogramming in cancer
Herbel, C., Patsoukis, N., Bardhan, K., Seth, P., Weaver, J. D., & Boussiotis, V. A. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0110-9 · Cited by 99
TET2 in Normal and Malignant HematopoiesisPreprint
Bowman, R. L., & Levine, R. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026518 · Cited by 102
Self-citationDivergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness
Ostrander, E. L., Kramer, A. C., Mallaney, C., Celik, H., Koh, W. K., Fairchild, J., Haussler, E., Zhang, C. R., & Challen, G. A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.011 · Cited by 97
Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A., & Pecqueur, C. (2021) · Oncogene · doi:10.1038/s41388-021-02056-1 · Cited by 101
Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations
Ansari, R. E., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (2017) · Histopathology · doi:10.1111/his.13334 · Cited by 93
Epigenetic reprogramming of melanoma cells by vitamin C treatment
Gustafson, C. B., Yang, C., Dickson, K. M., Shao, H., Van Booven, D., Harbour, J. W., Liu, Z.-J., & Wang, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0087-z · Cited by 90
Epigenetics of myelodysplastic syndromes
Itzykson, R., & Fenaux, P. (2013) · Leukemia · doi:10.1038/leu.2013.343 · Cited by 91
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92
Identification of cell-type-specific mutations in nodal T-cell lymphomas
Nguyen, T. B., Sakata‐Yanagimoto, M., Asabe, Y., Matsubara, D., Kano, J., Yoshida, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2016.122 · Cited by 92
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 100
Self-citationBrain stem cells as the cell of origin in glioma
Modrek, A. S. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i1.43 · Cited by 90
Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02175.x · Cited by 93
The Impact of DNA Methylation in Hematopoietic Malignancies
Guillamot, M., Cimmino, L., & Aifantis, I. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.12.006 · Cited by 96
Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T. L., Tan, J. C., Parekh, V., Benson, D. G., Crossman, D. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1727 · Cited by 89
Yao, W., Wu, F., Zhang, W., Chuang, S., Thompson, J. S., Chen, Z., Zhang, S., Clipson, A., Wang, M., Liu, H., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5376 · Cited by 89
Self-citationEpigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Zhang, P., & Zhang, M. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00962-x · Cited by 91
Epigenetic Deregulation of Apoptosis in Cancers
Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 94
Alghamri, M. S., McClellan, B. L., Avvari, R., Thalla, R., Carney, S. V., Hartlage, C. S., Haase, S., Ventosa, M., Taher, A. W., Kamran, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh3243 · Cited by 89
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 92
Yamazaki, J., Jelı́nek, J., Lu, Y., Cesaroni, M., Madžo, J., Neumann, F., He, R. L., Taby, R. F., Vasanthakumar, A., Macrae, T. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0739 · Cited by 90
Self-citationAdvanced MR Imaging of Gliomas: An Update
Kao, H., Chiang, S.-W., Chung, H., Tsai, F. Y., & Chen, C. (2013) · BioMed Research International · doi:10.1155/2013/970586 · Cited by 89
Isocitrate dehydrogenase mutations in gliomas
Guo, C., Pirozzi, C. J., Lopez, G. Y., & Yan, H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd415 · Cited by 93
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
Mishra, P., Tang, W., Putluri, V., Dorsey, T. H., Jin, F., Wang, F., Zhu, D., Amable, L., Deng, T., Zhang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93815 · Cited by 91
Self-citationD-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in micePreprint
Akbay, E. A., Moslehi, J. J., Christensen, C. L., Saha, S. K., Tchaicha, J. H., Ramkissoon, S. H., Stewart, K. M., Carretero, J., Kikuchi, E., Zhang, H., et al. (2014) · Genes & Development · doi:10.1101/gad.231233.113 · Cited by 93
Self-citationMolecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
Precision therapy for lymphoma—current state and future directions
Intlekofer, A. M., & Younes, A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.137 · Cited by 91
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 90
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells
Raffel, S., Klimmeck, D., Falcone, M., Demir, A., Pouya, A., Zeisberger, P., Lutz, C., Tinelli, M., Bischel, O. E., Bullinger, L., et al. (2020) · Blood · doi:10.1182/blood.2019003654 · Cited by 91
Togami, K., Chung, S. S., Madan, V., Booth, C. A. G., Kenyon, C. M., Cabal‐Hierro, L., Taylor, J., Kim, S. S., Griffin, G. K., Ghandi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1513 · Cited by 90
Self-citationWakita, S., Yamaguchi, H., Omori, I., Terada, K., Ueda, T., Manabe, E., Kurosawa, S., Iida, S., Ibaraki, T., Sato, Y., et al. (2012) · Leukemia · doi:10.1038/leu.2012.317 · Cited by 90
Arai, M., Nobusawa, S., Ikota, H., Takemura, S., & Nakazato, Y. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0085-1 · Cited by 88
Wrzeszczyński, K. O., Varadan, V., Byrnes, J., Lum, E., Kamalakaran, S., Levine, D. A., Dimitrova, N., Zhang, M. Q., & Lucito, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028503 · Cited by 89
Metabolic dependencies and vulnerabilities in leukemiaPreprint
Rashkovan, M., & Ferrando, A. A. (2019) · Genes & Development · doi:10.1101/gad.326470.119 · Cited by 92
Thomson, J. P., Hunter, J. M., Lempiäinen, H., Müller, A., Terranova, R., Moggs, J. G., & Meehan, R. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt232 · Cited by 87
5-Hydroxymethylcytosine – the elusive epigenetic mark in mammalian DNA
Kriukienė, E., Liutkevičiūtė, Z., & Klimašauskas, S. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35104h · Cited by 92
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
Atlante, S., Visintin, A., Marini, E., Savoia, M., Dianzani, C., Giorgis, M., Sürün, D., Maione, F., Schnütgen, F., Farsetti, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0802-8 · Cited by 87
Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer
Bhardwaj, V., & He, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103412 · Cited by 88
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
Chen, F., Bian, K., Tang, Q., Fedeles, B. I., Singh, V., Humulock, Z. T., Essigmann, J. M., & Li, D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00009 · Cited by 91
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets
Eifert, C., & Powers, S. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3299 · Cited by 90
Boutzen, H., Saland, E., Larrue, C., de Toni, F., Gales, L., Castelli, F. A., Cathebas, M., Zaghdoudi, S., Stuani, L., Kaoma, T., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150736 · Cited by 92
Qu, Y., Lennartsson, A., Gaidzik, V. I., Deneberg, S., Karimi, M., Bengtzén, S., Höglund, M., Bullinger, L., Döhner, K., & Lehmann, S. (2014) · Epigenetics · doi:10.4161/epi.29315 · Cited by 92
The evolving genomic landscape of myeloproliferative neoplasms
Nangalia, J., & Green, T. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.287 · Cited by 87
Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2344 · Cited by 88
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 91
Epigenetic Regulators as the Gatekeepers of Hematopoiesis
Rodrigues, C. P., Shvedunova, M., & Akhtar, A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.09.015 · Cited by 99
The Role of Host Cell DNA Methylation in the Immune Response to Bacterial Infection
Qin, W., Scicluna, B. P., & van der Poll, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696280 · Cited by 91
Damm, F., Thol, F. R., Hollink, I. H. I. M., Zimmermann, M., Reinhardt, K., van den Heuvel‐Eibrink, M. M., Zwaan, C. M., de Haas, V., Creutzig, U., Klusmann, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.142 · Cited by 87
CAPRI: efficient inference of cancer progression models from cross-sectional data
Ramazzotti, D., Caravagna, G., Loohuis, L. M. O., Graudenzi, A., Korsunsky, I., Mauri, G., Antoniotti, M., & Mishra, B. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv296 · Cited by 85
Reprogramming of central carbon metabolism in cancer stem cells
Wong, T. L., Che, N., & Ma, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.05.012 · Cited by 86
Hegi, M. E., Janzer, R.-C., Lambiv, W. L., Gorlia, T., Kouwenhoven, M. C. M., Hartmann, C. J., von Deimling, A., Martinet, D., Schmutz, N. B., Diserens, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0938-4 · Cited by 84
Chicken or the egg: Warburg effect and mitochondrial dysfunction
Senyilmaz, D., & Teleman, A. A. (2015) · F1000Prime Reports · doi:10.12703/p7-41 · Cited by 89
Metabolite sensing and signaling in cancer
Wang, Y.-P., Li, J., Qu, J., Yin, M., & Lei, Q. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.007624 · Cited by 87
Liaghat, M., Ferdousmakan, S., Mortazavi, S. H., Yahyazadeh, S., Irani, A., Banihashemi, S., Asl, F. S. S., Akbari, A., Farzam, F., Aziziyan, F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01957-4 · Cited by 87
Choi, C., Ganji, S., Hulsey, K., Madan, A., Kovács, Z. Z., Dimitrov, I. E., Zhang, S., Pichumani, K., Mendelsohn, D. B., Mickey, B., et al. (2013) · NMR in Biomedicine · doi:10.1002/nbm.2943 · Cited by 83
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 89
Casalino, L., & Verde, P. (2020) · Genes · doi:10.3390/genes11080922 · Cited by 83
D-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 87
Metabolic tricks of cancer cells
Hönigová, K., Navrátil, J., Peltanová, B., Polanska, H. H., Raudenská, M., & Masařík, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188705 · Cited by 84
Lin, C., Hou, H., Chou, W., Kuo, Y., Liu, C., Chen, C., Lai, Y.-J., Tseng, M., Huang, C., Chiang, Y., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23596 · Cited by 85
R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
Ye, D., Ma, S., Xiong, Y., & Guan, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
Jiang, L., Boufersaoui, A., Yang, C., Ko, B., Rakheja, D., Guevara, G., Hu, Z., & DeBerardinis, R. J. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.11.004 · Cited by 84
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Epigenomics of cancer – emerging new concepts
Hassler, M. R., & Egger, G. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.007 · Cited by 85
Badur, M. G., Muthusamy, T., Parker, S. J., Ma, S., McBrayer, S. K., Cordes, T., Magaña, J. H., Guan, K., & Metallo, C. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.074 · Cited by 87
Deneberg, S., Guardiola, P., Lennartsson, A., Qu, Y., Gaidzik, V., Blanchet, O., Karimi, M., Bengtzén, S., Nahi, H., Uggla, B., et al. (2011) · Blood · doi:10.1182/blood-2011-01-332353 · Cited by 84
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 85
Mitochondria signaling to the epigenome: A novel role for an old organelle
Santos, J. H. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.016 · Cited by 84
High-Dose Vitamin C for Cancer Therapy
Mussa, A., Idris, R. A. M., Ahmed, N., Ahmad, S., Murtadha, A. H., Din, T. A. D. A. T., Yean, C. Y., Rahman, W. F. W. A., Lazim, N. M., Uskoković, V., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15060711 · Cited by 85
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 81
Mulholland, S. A., Pearson, D. M., Hamoudi, R., Malley, D. S., Smith, C. M., Weaver, J. M. J., Jones, D., Kocialkowski, S., Bäcklund, L. M., Collins, V. P., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26499 · Cited by 81
Age-related epigenetic drift in the pathogenesis of MDS and AMLPreprint
Maegawa, S., Gough, S. M., Watanabe‐Okochi, N., Lu, Y., Zhang, N., Castoro, R. J., Estecio, M. R., Jelı́nek, J., Liang, S., Kitamura, T., et al. (2014) · Genome Research · doi:10.1101/gr.157529.113 · Cited by 83
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases
Tarhonskaya, H., Rydzik, A. M., Leung, I. K. H., Loik, N. D., Chan, M. C., Kawamura, A., McCullagh, J. S. O., Claridge, T. D. W., Flashman, E., & Schofield, C. J. (2014) · Nature Communications · doi:10.1038/ncomms4423 · Cited by 80
Cancer Epigenetics: New Therapies and New Challenges
Hatzimichael, E. C., & Crook, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/529312 · Cited by 85
The genetic landscape of anaplastic astrocytoma
Killela, P. J., Pirozzi, C. J., Reitman, Z. J., Jones, S., Rasheed, B. A., Lipp, E., Friedman, H. S., Friedman, A. H., He, Y., McLendon, R. E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1505 · Cited by 80
Metabolic traits of cancer stem cells
Peixoto, J., & Lima, J. P. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033464 · Cited by 81
Metabolism as master of hematopoietic stem cell fate
Ito, K., Bonora, M., & Ito, K. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2534-z · Cited by 85
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
